Why would ACT issue a press release in variance from the actual paper published in Nature? To garner a mountain free, positive publicity, to be sure. But to what end? Follow the money. Here is a potential answer. In the wake of this mass media stampede, ACT’s stock has risen about 400%. Investors should do their due diligence more carefully. ACT has a history of money problems temporarily remedied by hyped stories about their supposed breakthroughs that later turn out to have been less than meets the eye.
Time is short, so I’ll be direct: FIRST THINGS needs you. And we need you by December 31 at 11:59 p.m., when the clock will strike zero. Give now at supportfirstthings.com.
First Things does not hesitate to call out what is bad. Today, there is much to call out. Yet our editors, authors, and readers like you share a greater purpose. And we are guided by a deeper, more enduring hope.
Your gift of $50, $100, or even $250 or more will bring this message of hope to many more people in the new year.
Make your gift now at supportfirstthings.com.
First Things needs you. I’m confident you’ll answer the call.
